NUDT1 and neoplasm: The peptide- and hyaluronic acid-modified polyplex provided 1.2-fold higher knockout efficiency of the target gene MTH1 compared with the commercial transfection agent Lipofectamine 3000, and exerted tumor-suppressing activity that correlated with reduced expression of MTH1 in tumor tissue.